Relapsed/Refractory Multiple Myeloma Pipeline 2025: Innovative Clinical Developments by Over 55 Global Companies - DelveInsight | Highlighting Bristol-Myers Squibb, I-MAB Biopharma, Pfizer, Arcellx

DelveInsight's, "Relapsed/Refractory Multiple Myeloma Pipeline Insight, 2025" report provides comprehensive insights about 55+ companies and 60+ pipeline drugs in Relapsed/Refractory Multiple Myeloma pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Relapsed/Refractory Multiple Myeloma compsnies are Gilead Sciences, Novartis, Array Biopharma, Hrain Biotechnology Co., Ltd., Cartesian Therapeutics, Xencor, Takeda, Sorrento Therapeutics, Heidelberg Pharma AG, Ichnos Sciences, Allogene Therapeutics, Harpoon Therapeutics, Cellectis, Poseida Therapeutics, Regeneron Pharmaceuticals, ONK Therapeutics, TeneoOne, iTeos Therapeutics, Oricell Therapeutics, Anaveon AG, Luminary Therapeutics, Seagen Inc., Trillium Therapeutics Inc., Virtuoso BINco, Inc., and others.

As relapsed/refractory multiple myeloma (RRMM) continues to rise globally and contributes to comorbidities such as diabetes, cardiovascular disease, and certain cancers, there is an increasing need for safer and more effective therapies. According to DelveInsight, the RRMM pipeline features over 55 pharmaceutical and biotech companies developing more than 60 therapeutic candidates across various stages of clinical and preclinical development, highlighting the significant innovation and dedication to tackling this critical public health issue.

DelveInsight's report, "Relapsing Refractory Multiple Myeloma Pipeline Insight 2025," offers a comprehensive and strategic review of the R&D landscape. It details clinical trial progress, emerging therapies, mechanisms of action, competitive positioning, and key company initiatives. The report serves as an essential reference for researchers, healthcare investors, and decision-makers, providing insights into the evolving RRMM therapeutics market and the breakthroughs shaping its future trajectory.

Explore the Cutting-Edge Landscape of Relapsing refractory multiple myeloma Drug Development @ https://www.delveinsight.com/report-store/relapsing-refractory-multiple-myeloma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Key Takeaways from the Relapsing refractory multiple myeloma Pipeline Report

*
DelveInsight's Relapsed/Refractory Multiple Myeloma (RRMM) pipeline report highlights a dynamic landscape with over 55 companies actively developing more than 60 therapeutic candidates for RRMM treatment.

*
In April 2024, the FDA expanded the use of Abecma, permitting its administration earlier in the treatment sequence for RRMM patients who have undergone two or more prior therapies, including an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 monoclonal antibody. Additionally, on August 9, 2023, the FDA approved talquetamab for adults with RRMM who have received at least four prior lines of therapy.

*
Leading companies working on new RRMM treatments include Bristol-Myers Squibb, I-MAB Biopharma, Pfizer, Arcellx, Gilead Sciences, Novartis, Array Biopharma, Hrain Biotechnology Co., Ltd., Cartesian Therapeutics, Xencor, Takeda, Sorrento Therapeutics, Heidelberg Pharma AG, Ichnos Sciences, Allogene Therapeutics, Harpoon Therapeutics, Cellectis, Poseida Therapeutics, Regeneron Pharmaceuticals, ONK Therapeutics, TeneoOne, iTeos Therapeutics, Oricell Therapeutics, Anaveon AG, Luminary Therapeutics, Seagen Inc., Trillium Therapeutics Inc., Virtuoso BINco, Inc., and others, all aiming to enhance the RRMM treatment landscape.

*
Promising pipeline therapies in various stages of development include Mezigdomide, Iopofosine, ORIC-533, and several additional candidates.

Relapsing refractory multiple myeloma Overview:

Multiple myeloma (MM) is a type of blood cancer characterized by the abnormal proliferation of monoclonal plasma cells in the bone marrow and, occasionally, other tissues. Relapsed/refractory multiple myeloma (RRMM) refers to cases where the disease returns after treatment or does not respond at all. Resistance often develops due to genetic mutations that help cancer cells evade therapies and alter their environment to protect themselves from the immune system.

MM frequently begins as monoclonal gammopathy of undetermined significance (MGUS), a usually benign condition in which abnormal plasma cells are present without causing symptoms or organ damage. MGUS affects over 3% of individuals over the age of 50 and carries an approximate 1% annual risk of progressing to MM.

Common symptoms of MM include bone pain, fatigue, weight loss, and recurrent infections. Less frequent signs include hepatomegaly, splenomegaly, lymphadenopathy, and rare complications such as spinal cord compression or peripheral neuropathy, which may suggest related conditions like amyloidosis or POEMS syndrome.

Diagnosis follows NCCN guidelines and typically involves blood tests (CBC, kidney function, calcium, albumin, LDH, beta-2 microglobulin), serum and urine protein studies, and free light chain assays.

Treatment advances for RRMM include novel agents such as thalidomide, bortezomib, and lenalidomide, used alone or in combination with dexamethasone. These therapies have laid the groundwork for newer drugs like pomalidomide and carfilzomib, providing improved options for managing relapsed or refractory disease.

Download the Relapsing refractory multiple myeloma sample report to know in detail about the Relapsing refractory multiple myeloma treatment market @ https://www.delveinsight.com/sample-request/relapsing-refractory-multiple-myeloma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Relapsing refractory multiple myeloma Pipeline Analysis

The Relapsing refractory multiple myeloma pipeline insights report 2025, provides insights into:

*
Provides comprehensive insights into key companies developing therapies in the Relapsing refractory multiple myeloma Market.

*
Categorizes Relapsing refractory multiple myeloma therapeutic companies by development stage: early, mid, and late-stage.

*
Highlights major companies involved in targeted therapy development, including both active and inactive (paused/discontinued) projects.

*
Reviews emerging Relapsing refractory multiple myeloma drugs under development based on:

*
Stage of development

*
Relapsing refractory multiple myeloma Route of administration

*
Target receptor

*
Monotherapy vs. combination therapy

*
Relapsing refractory multiple myeloma Mechanism of action

*
Molecular type

*
Offers detailed analysis of:

*
Company-to-company and company-academia collaborations

*
Relapsing refractory multiple myeloma Licensing agreements

*
Funding and investment activities supporting future Relapsing refractory multiple myeloma market advancement.

Unlock key insights into emerging Relapsing refractory multiple myeloma therapies and market strategies here: https://www.delveinsight.com/report-store/relapsing-refractory-multiple-myeloma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Relapsing refractory multiple myeloma Emerging Drugs

*
Mezigdomide: Bristol-Myers Squibb

Cereblon E3 ligase modulators (CELMoDs) are oral therapies that boost immune responses and destroy cancer cells by targeting and degrading proteins essential for tumor survival. Bristol Myers Squibb is advancing two next-generation CELMoDs, mezigdomide and iberdomide, for multiple myeloma treatment. These drugs are intended to provide greater effectiveness compared to current immunomodulatory agents (IMiDs), while offering manageable side effects, convenient oral administration, and the potential for improved patient outcomes.

*
Iopofosine: Cellectar Biosciences, Inc.

Iopofosine is a small-molecule Phospholipid Drug Conjugate Trademark designed to deliver the radioisotope iodine-131 directly to cancer cells, reducing exposure to healthy tissues. This targeted mechanism differentiates iopofosine from many conventional therapies. It is currently under investigation in multiple studies, including the CLOVER-WaM Phase 2 pivotal trial for relapsed/refractory Waldenstrom's macroglobulinemia (r/r WM), a Phase 2b trial for relapsed/refractory multiple myeloma (r/r MM), and the CLOVER-2 Phase 1 study for various pediatric cancers.

Relapsing refractory multiple myeloma Pipeline Therapeutic Assessment

Relapsing refractory multiple myeloma Assessment by Product Type

- Mono

- Combination

- Mono/Combination

Relapsing refractory multiple myeloma By Stage

- Late-stage products (Phase III)

- Mid-stage products (Phase II)

- Early-stage product (Phase I) along with the details of

- Pre-clinical and Discovery stage candidates

- Discontinued & Inactive candidates

Relapsing refractory multiple myeloma Assessment by Route of Administration

- Oral

- Parenteral

- Intravenous

- Subcutaneous

- Topical

Relapsing refractory multiple myeloma Assessment by Molecule Type

- Recombinant fusion proteins

- Small molecule

- Monoclonal antibody

- Peptide

- Polymer

- Gene therapy

Download sample pages to get an in-depth assessment of the emerging Relapsing refractory multiple myeloma therapies and key Relapsing refractory multiple myeloma companies: https://www.delveinsight.com/sample-request/relapsing-refractory-multiple-myeloma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Table of Contents

1. Report Introduction

2. Executive Summary

3. Relapsing refractory multiple myeloma Current Treatment Patterns

4. Relapsing refractory multiple myeloma - DelveInsight's Analytical Perspective

5. Therapeutic Assessment

6. Relapsing refractory multiple myeloma Late-Stage Products (Phase-III)

7. Relapsing refractory multiple myeloma Mid-Stage Products (Phase-II)

8. Early Stage Products (Phase-I)

9. Pre-clinical Products and Discovery Stage Products

10. Inactive Products

11. Dormant Products

12. Relapsing refractory multiple myeloma Discontinued Products

13. Relapsing refractory multiple myeloma Product Profiles

14. Relapsing refractory multiple myeloma Key Companies

15. Relapsing refractory multiple myeloma Key Products

16. Dormant and Discontinued Products

17. Relapsing refractory multiple myeloma Unmet Needs

18. Relapsing refractory multiple myeloma Future Perspectives

19. Relapsing refractory multiple myeloma Analyst Review

20. Appendix

21. Report Methodology

Request the sample PDF to get detailed insights about the Relapsing refractory multiple myeloma pipeline reports offerings: https://www.delveinsight.com/report-store/relapsing-refractory-multiple-myeloma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=relapsedrefractory-multiple-myeloma-pipeline-2025-innovative-clinical-developments-by-over-55-global-companies-delveinsight-highlighting-bristolmyers-squibb-imab-biopharma-pfizer-arcellx]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/

Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com



This release was published on openPR.